Skip to main content
Nature Portfolio logoLink to Nature Portfolio
. 2025 Jul 3;6(7):1295. doi: 10.1038/s43018-025-01026-w

Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial

Wen Lei 1,2,#, Hui Liu 1,#, Wenhai Deng 3,#, Wei Chen 4,#, Yun Liang 1, Wenxia Gao 4, Xianggui Yuan 1, Shanshan Guo 1, Ping Li 5, Jinyong Wang 6, Xiangmin Tong 7,, Yi Eve Sun 4,, Aibin Liang 5,, Wenbin Qian 1,2,
PMCID: PMC12296552  PMID: 40610723

Correction to: Nature Cancer 10.1038/s43018-025-00940-3, published online 18 April 2025.

In the version of the article initially published, due to an error in figure assembly, the sixth mouse in the “19 CAR-NK” (Day 2) images in Fig. 1d was a duplicate of the second mouse in the same group. Additionally, the “18.2 CAR-NK” (Day 37) mouse image was a duplicate of the sixth “18.2 CAR-NK” (Day 30) mouse directly above it. The amended figure with the correct images is now available in the HTML and PDF versions of the article.

Contributor Information

Xiangmin Tong, Email: tongxiangmin@163.com.

Yi Eve Sun, Email: yi.eve.sun@gmail.com.

Aibin Liang, Email: lab7182@tongji.edu.cn.

Wenbin Qian, Email: qianwb@zju.edu.cn.


Articles from Nature Cancer are provided here courtesy of Nature Publishing Group

RESOURCES